Research progress on insulin-like growth factor-binding protein-4 as a marker of vulnerable atherosclerotic plaque
Received:October 08, 2018  Revised:October 27, 2018
View Full Text  View/Add Comment  Download reader
DOI:10.11915/j.issn.1671-5403.2019.01.013
Key words:insulin-like growth factor-binding protein 4; acute coronary syndrome; metalloproteinase
Author NameAffiliationE-mail
DAI Xin-Chun Department of Cardiology, the First Affiliated Hospital, Air force Medical University, Xi′an 710032, China  
CAO Feng the Second Medical Center of Chinese PLA General Hospital, 100853, China;National Clinical Research Center for Geriatric Diseases, Beijing 100853, China fengcao8828@163.com 
Hits: 283
Download times: 299
Abstract:
      Vulnerable plaque is one of the important risk factors for major adverse cardiovascular events, and its early detection and effective intervention are of great clinical significance. Insulin-like growth factor (IGF) binding protein-4 (IGFBP-4) is a substrate of pregnancy-associated plasma protein-A (PAPP-A) in vulnerable plaques and mediates the release of IGF, which is likely to accelerate atherogenesis. Thus, IGFBP-4 serves as one of the important biomarkers of vulnerable plaque. Vulnerable plaque is the pathologenic basis of acute coronary syndrome and a much sought-after focus in cardiovascular field. In this article, we reviewed the role of IGFBP-4 in the development of vulnerable plaque and its potential in assessing plaque vulnerability and major adverse cardiovascular events.
Close